The first patient with drug-resistant epilepsy has received LivaNova’s (NASDAQ:LIVN) vagus nerve stimulation (VNS) therapy system, kicking off enrollment of a global registry to evaluate it, the company said.
Drug-resistant epilepsy (DRE) affects nearly one in three people with epilepsy, according to an article in the New England Journal of Medicine. The LivaNova study will enroll up to 2,000 patients with five-year follow-up data, yielding one of the largest data sets in the world for DRE patients treated with various generations of VNS therapy. Data from the CORE-VNS study will contribute to the body of research related to this disease state and advance the science behind VNS therapy by evaluating the safety, effectiveness and clinical outcomes for patients.
Get the full story on our sister site, Medical Design & Outsourcing.
